CM
ABUS icon

Caption Management’s Arbutus Biopharma ABUS Stock Holding History

Caption Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-41,866
Closed -$129K – 1612
2025
Q2 		$129K Buy
41,866
+17,669
+73% +$58.7K ﹤0.01% 1301
2025
Q1 		$84.4K Sell
24,197
-45,403
-65% -$151K ﹤0.01% 1369
2024
Q4 		$228K Buy
+69,600
New +$256K ﹤0.01% 1253
2024
Q1 		– Sell
-42,736
Closed -$111K – 1135
2023
Q4 		$107K Buy
42,736
+40,065
+1,500% +$78.5K ﹤0.01% 1173
2023
Q3 		$5.42K Buy
+2,671
New +$5.6K ﹤0.01% 1228
2023
Q1 		– Sell
-50,000
Closed -$141K – 1038
2022
Q4 		$117K Buy
50,000
+16,216
+48% +$38.8K ﹤0.01% 1118
2022
Q3 		$64K Sell
33,784
-17,016
-33% -$40.1K ﹤0.01% 1369
2022
Q2 		$138K Buy
50,800
+31,720
+166% +$81.2K ﹤0.01% 1269
2022
Q1 		$58K Buy
19,080
+3,983
+26% +$12.2K ﹤0.01% 1355
2021
Q4 		$59K Buy
15,097
+8,199
+119% +$31.8K ﹤0.01% 1506
2021
Q3 		$30K Sell
6,898
-31,802
-82% -$106K ﹤0.01% 1440
2021
Q2 		$118K Buy
+38,700
New +$120K ﹤0.01% 1213
2019
Q1 		– Sell
-5,000
Closed -$20K – 542
2018
Q4 		$20K Buy
+5,000
New +$24.6K ﹤0.01% 449

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Caption Management's ABUS Position: Q3 2025 in Review

Caption Management sold out of Arbutus Biopharma (ABUS) in Q3 2025, closing a stake of 41,866 shares — an estimated $129K sold.

Caption Management first reported a position in ABUS in Q4 2018 and held it in 13 quarters. The position peaked at $228K in Q4 2024. 166 funds tracked by Wall St. Rank hold ABUS as of Q3 2025.

  • Caption Management reported no remaining Arbutus Biopharma position as of Q3 2025 after selling out during the quarter.
  • Caption Management sold 41,866 Arbutus Biopharma shares in Q3 2025, an estimated $129K.
  • Caption Management first reported a position in Arbutus Biopharma in Q4 2018 and held it in 13 quarters.
  • Caption Management's Arbutus Biopharma position peaked at $228K in Q4 2024.
  • 166 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2025.

Based on Caption Management's 13F filing for Q3 2025, filed 14 Nov 2025.